Trial Profile
A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND 4
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Mar 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been discontinued in the Ireland.
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.